益佰制药(600594) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter reached CNY 824,808,482.41, representing a year-on-year growth of 19.99%[7] - Net profit attributable to shareholders increased by 18.63% to CNY 70,987,858.89 compared to the same period last year[7] - Basic earnings per share increased by 18.42% to CNY 0.090 per share[7] - Net profit for Q1 2021 was CNY 67.13 million, representing a 22.6% increase compared to CNY 54.73 million in Q1 2020[39] - Total operating revenue for Q1 2021 reached CNY 824.81 million, a 20% increase from CNY 687.40 million in Q1 2020[39] - The total profit for Q1 2021 was ¥34,778,022.59, an increase of 14.4% from ¥30,380,297.43 in Q1 2020[43] Cash Flow and Liquidity - The net cash flow from operating activities surged by 101.64% to CNY 412,834,296.40 compared to the previous year[7] - Cash and cash equivalents increased by 63.15% to CNY 1,007,370,015.20, primarily due to increased pharmaceutical sales collections[15] - Cash and cash equivalents at the end of Q1 2021 totaled ¥1,007,370,015.20, a decrease from ¥1,541,387,083.68 in Q1 2020[47] - The net cash flow from investment activities was 81,373,251.87 RMB, compared to a negative cash flow of -21,515,238.13 RMB in the previous period[50] - Cash and cash equivalents at the end of the period totaled 764,739,019.67 RMB, an increase from 390,969,486.35 RMB at the beginning of the period[50] Assets and Liabilities - Total assets increased by 2.25% to CNY 5,343,834,797.57 compared to the end of the previous year[7] - The company's total liabilities increased to RMB 1,812,811,632.30 from RMB 1,763,260,831.85, marking a rise of approximately 2.8%[31] - The company's equity attributable to shareholders rose to RMB 3,435,482,593.13 from RMB 3,365,164,558.12, an increase of about 2.1%[31] - Total current liabilities were CNY 1,490,079,107.11, while total liabilities stood at CNY 1,530,010,853.16[59] Research and Development - R&D expenses increased by 212.42% to ¥28,522,335.87 compared to ¥9,129,560.41 in Q3 2020, primarily due to increased investment in research and development[18] - Research and development expenses increased significantly to CNY 28.52 million, up from CNY 9.13 million in the previous year, reflecting a focus on innovation[39] - Research and development expenses surged to ¥14,174,032.61, a significant increase from ¥1,228,584.30, reflecting a growth of 1,051.5%[42] Shareholder Information - The number of shareholders reached 55,770 by the end of the reporting period[12] Legal and Operational Issues - The company is in litigation regarding the sale of 78.57% equity in Harbin Yibai Medical, with a claim for breach of contract totaling ¥21,100,000[20] - The subsidiary, Harbin Yibai Medical, is facing significant operational uncertainties due to frozen assets and ongoing legal disputes[22] - The company has initiated a legal process regarding a construction project dispute, with a claim for payment of ¥854,399.00 pending in court[23] Borrowings and Financial Expenses - Long-term borrowings increased by 158.40% to CNY 243,880,389.63 due to new long-term loans[17] - The company reported a significant increase in financial expenses, amounting to ¥14,317,800.99, compared to a negative expense of ¥1,739,207.22 in Q3 2020, mainly due to last year's fiscal subsidies[18] - The company raised 126,900,000.00 RMB in borrowings, significantly up from 66,900,000.00 RMB in the previous period[50] Inventory and Accounts Receivable - Accounts receivable decreased to RMB 268,456,482.31 from RMB 316,869,794.02, a decline of about 15.3%[29] - Inventory increased to RMB 525,287,757.06 from RMB 498,362,492.04, reflecting a rise of approximately 5.4%[29]